Juno Therapeutics (JUNO) has risen sharply, recording gains of 4.3% in the past 4 weeks. However, the stock has corrected -2.63% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.52% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.31% and the fifty day Moving Average is 4.83%. Juno Therapeutics Inc. has dropped 23.26% during the last three month period . Year-to-Date the stock performance stands at -26.63%.
Juno Therapeutics (JUNO) : The highest level Juno Therapeutics (JUNO) is projected to reach is $61 for the short term and the lowest estimate is at $41. The consolidated price target from 8 rating analysts who initiate coverage on the stock is $48.75 and the possibility the share price can swing is $6.04.
Juno Therapeutics (NASDAQ:JUNO): stock turned positive on Friday. Though the stock opened at $31.75, the bulls momentum made the stock top out at $32.75 level for the day. The stock recorded a low of $31.51 and closed the trading day at $32.26, in the green by 2.19%. The total traded volume for the day was 1,115,418. The stock had closed at $31.57 in the previous days trading.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.